USPTO serial 79136686
SPLENDRIS
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Nov 25, 2014
- Examiner
- COLEMAN, NICHOLAS A
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with SPLENDRIS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Owner
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.
518040 Shenzhen, Guangdong, CN
Other trademarks owned by SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.
518040 Shenzhen, Guangdong, CN
Other trademarks owned by SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.
SHENZHEN SALUBRIS; PHARMACEUTICALS CO., LTD.
518040 Shenzhen, Guangdong, CN
Other trademarks owned by SHENZHEN SALUBRIS; PHARMACEUTICALS CO., LTD.
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Timothy T. Wang
TIMOTHY T. WANG Ni, Wang & Massand, PLLC8140 Walnut Hill Lane, Suite 500Dallas, TX 75231UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations, for treating diseases of cardiovascular system, for use in haematology, dermatology, ophthalmology and gastroenterology, anti-infectives, antitumor drugs, for treating metabolic diseases, for treating nervous system diseases, for treating diseases of respiratory system, digestive system, endocrine system and immune system, for treating hypersensitivity diseases and for treating musculo-skeletal disorders; Chemico-pharmaceutical preparations, for the prevention and treatment of disorders of the nervous system, the immune system, the cardiovascular system, the metabolic system, the respiratory system, the musculo-skeletal system, digestive system and endocrine system, for the treatment of infective diseases, for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for treating hypersensitivity diseases; Chemical preparations for pharmaceutical purposes, for treating diseases of cardiovascular system, for use in haematology, dermatology, ophthalmology and gastroenterology, anti-infectives, antitumor drugs, for treating metabolic diseases, for treating nervous system diseases, for treating diseases of respiratory system, digestive system, endocrine system and immune system, for treating hypersensitivity diseases and for treating musculo-skeletal disorders; Medicines for human purposes, for treating diseases of cardiovascular system, for use in haematology, dermatology, ophthalmology and gastroenterology, anti-infectives, antitumor drugs, for treating metabolic diseases, for treating nervous system diseases, for treating diseases of respiratory system, digestive system, endocrine system and immune system, for treating hypersensitivity diseases and for treating musculo-skeletal disorders; Medicated troches, for the prevention and treatment of disorders of the nervous system, the immune system, the cardiovascular system, the metabolic system, the respiratory system, the musculo-skeletal system, digestive system, and endocrine system, for the treatment of infective diseases, for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Active pharmaceutical ingredients in the nature of pharmaceutical preparations, which are used for the prevention and treatment of disorders of the nervous system, the immune system, the cardiovascular system, the metabolic system, the respiratory system, the musculo-skeletal system, digestive system, and endocrine system, for the treatment of infective diseases, for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Prepared Chinese medicines, for treating diseases of cardiovascular system, for use in haematology, dermatology, ophthalmology and gastroenterology, anti-infectives, antitumor drugs, for treating metabolic diseases, for treating nervous system diseases, for treating diseases of respiratory system, digestive system, endocrine system and immune system, for treating hypersensitivity diseases and for treating musculo-skeletal disorders; Biochemical medicines, for treating diseases of cardiovascular system, for use in haematology, dermatology, ophthalmology and gastroenterology, anti-infectives, antitumor drugs, for treating metabolic diseases, for treating nervous system diseases, for treating diseases of respiratory system, digestive system, endocrine system and immune system, for treating hypersensitivity diseases and for treating musculo-skeletal disorders; Dietetic substances adapted for medical use, namely, beverages or food in the nature of vitamin, protein, minerals, lecithin, glucose, amino acid, folic acid, fruit juice, fruit oil, honey, seaweed glue, fish oil, cod-liver oil, cubilose, and mineral food-supplements, which are used for treating diseases of cardiovascular system, for use in haematology, dermatology, ophthalmology and gastroenterology, anti-infectives, antitumor drugs, for treating metabolic diseases, for treating nervous system diseases, for treating diseases of respiratory system, digestive system, endocrine system and immune system for treating hypersensitivity diseases and for treating musculo-skeletal disorders; Drugs for medical purposes, namely, medicines for the prevention and treatment of disorders of the nervous system, the immune system, the cardiovascular system, the metabolic system, the respiratory system, the musculo-skeletal system, digestive system, and endocrine system, for the treatment of infective diseases, for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders | SECTION 71 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.
- Other trademarks owned by SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.
- Other trademarks owned by SHENZHEN SALUBRIS; PHARMACEUTICALS CO., LTD.
- Other trademarks in Class 005
- Similar marks named SPLENDRIS
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Nov 26, 2023 | DENC | NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED | — |
| Nov 26, 2023 | DETH | DEATH OF INTERNATIONAL REGISTRATION | — |
| Jul 11, 2022 | INNT | TOTAL INVALIDATION PROCESSED BY THE IB | — |
| Jun 9, 2022 | XXSS | GENERIC MADRID TRANSACTION SENT TO IB | — |
| Jun 8, 2022 | XXCR | GENERIC MADRID TRANSACTION CREATED | — |
| Feb 11, 2022 | INTR | TOTAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| Jun 11, 2021 | C71T | CANCELLED SECTION 71 | — |
| Nov 25, 2019 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Oct 9, 2019 | CORN | CORRECTION FROM THE IB EXAMINED, NO ACTION IS NEEDED | — |
| Jul 5, 2019 | CRCV | CORRECTION TRANSACTION RECEIVED FROM IB | — |
| Jul 4, 2019 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Dec 7, 2018 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| May 8, 2015 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Apr 20, 2015 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Apr 20, 2015 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Mar 12, 2015 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Feb 25, 2015 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Nov 25, 2014 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Sep 9, 2014 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Sep 9, 2014 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Aug 20, 2014 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Aug 7, 2014 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Aug 5, 2014 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Aug 5, 2014 | ALIE | ASSIGNED TO LIE | — |
| Jul 27, 2014 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jul 27, 2014 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jul 27, 2014 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Jul 27, 2014 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Jul 27, 2014 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jun 11, 2014 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jun 11, 2014 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 11, 2014 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Dec 17, 2013 | CNFR | FINAL REFUSAL MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Dec 16, 2013 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Nov 20, 2013 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Nov 20, 2013 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Nov 20, 2013 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 14, 2013 | RFNT | REFUSAL PROCESSED BY IB | — |
| Oct 23, 2013 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Oct 22, 2013 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Oct 21, 2013 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Oct 20, 2013 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 16, 2013 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Oct 13, 2013 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 12, 2013 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Oct 10, 2013 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |